Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
3.610
-0.600 (-14.25%)
Nov 16, 2026, 4:00 PM EST - Market closed

Relmada Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-65-56.2-83.89-103.7-161.25-125.7
Net Income
-65.7-57.39-79.98-98.79-157.04-125.75
Earnings Per Share
-0.71-1.45-2.65-3.28-5.30-7.16
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
202.1293.0144.9196.32148.32211.91
Total Debt
------
Net Cash (Debt)
202.1293.0144.9196.32148.32211.91
Net Cash Growth
1355.54%107.10%-53.38%-35.06%-30.01%80.98%
Net Cash Per Share
2.172.361.493.205.0112.07

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-51.86-45.79-51.76-51.66-103.8-91.87
Capital Expenditures
------
Free Cash Flow
-51.86-45.79-51.76-51.66-103.8-91.87
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.